Black Diamond Therapeutics Stock Performance
| BDTX Stock | USD 2.51 0.03 1.18% |
The firm shows a Beta (market volatility) of 2.38, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Black Diamond will likely underperform. At this point, Black Diamond Therap has a negative expected return of -1.32%. Please make sure to confirm Black Diamond's total risk alpha, as well as the relationship between the kurtosis and price action indicator , to decide if Black Diamond Therap performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Black Diamond Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in December 2024. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
Actual Historical Performance (%)
One Day Return 2.16 | Five Day Return 1.76 | Year To Date Return (10.83) | Ten Year Return (93.43) | All Time Return (93.43) |
1 | HC Wainwright Reaffirms Buy Rating for Black Diamond Therapeutics - MarketBeat | 09/04/2024 |
2 | Insider Trading | 09/13/2024 |
3 | Acquisition by Erika Jones of 100000 shares of Black Diamond at 4.86 subject to Rule 16b-3 | 09/17/2024 |
4 | Acquisition by Raman Prakash of 2694 shares of Black Diamond at 4.78 subject to Rule 16b-3 | 09/20/2024 |
5 | Black Diamond Therapeutics Lead Drug Candidate Shows Initial Anti-tumor Activity In Certain Type Of Lung Cancer Resistant To AstraZenecas Drug | 09/23/2024 |
6 | HC Wainwright Reiterates Buy Rating for Black Diamond Therapeutics | 09/26/2024 |
7 | Black Diamond Therapeutics to Participate in Upcoming Investor Conferences - StockTitan | 11/01/2024 |
8 | Black Diamond Therapeutics Buy Rating Reaffirmed at HC Wainwright | 11/07/2024 |
9 | Acquisition by Hatzis-schoch Brent of 200000 shares of Black Diamond at 4.86 subject to Rule 16b-3 | 11/08/2024 |
10 | T. Rowe Price Investment Management, Inc. Expands Stake in Black Diamond Therapeutics Inc | 11/14/2024 |
| Begin Period Cash Flow | 35.5 M |
Black |
Black Diamond Relative Risk vs. Return Landscape
If you would invest 627.00 in Black Diamond Therapeutics on August 27, 2024 and sell it today you would lose (376.00) from holding Black Diamond Therapeutics or give up 59.97% of portfolio value over 90 days. Black Diamond Therapeutics is currently does not generate positive expected returns and assumes 4.4006% risk (volatility on return distribution) over the 90 days horizon. In different words, 39% of stocks are less volatile than Black, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Black Diamond Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Black Diamond's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Black Diamond Therapeutics, and traders can use it to determine the average amount a Black Diamond's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.3007
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | BDTX |
Estimated Market Risk
| 4.4 actual daily | 39 61% of assets are more volatile |
Expected Return
| -1.32 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.3 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Black Diamond is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Black Diamond by adding Black Diamond to a well-diversified portfolio.
Black Diamond Fundamentals Growth
Black Stock prices reflect investors' perceptions of the future prospects and financial health of Black Diamond, and Black Diamond fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Black Stock performance.
| Return On Equity | -0.63 | ||||
| Return On Asset | -0.33 | ||||
| Current Valuation | 54.04 M | ||||
| Shares Outstanding | 56.59 M | ||||
| Price To Book | 1.48 X | ||||
| EBITDA | (86.02 M) | ||||
| Net Income | (82.44 M) | ||||
| Cash And Equivalents | 160.89 M | ||||
| Cash Per Share | 4.43 X | ||||
| Total Debt | 25.3 M | ||||
| Debt To Equity | 0.19 % | ||||
| Current Ratio | 8.55 X | ||||
| Book Value Per Share | 1.72 X | ||||
| Cash Flow From Operations | (66.72 M) | ||||
| Earnings Per Share | (1.33) X | ||||
| Market Capitalization | 143.73 M | ||||
| Total Asset | 158.57 M | ||||
| Retained Earnings | (417.43 M) | ||||
| Working Capital | 114.39 M | ||||
| Current Asset | 123.51 M | ||||
| Current Liabilities | 4.43 M | ||||
About Black Diamond Performance
Evaluating Black Diamond's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Black Diamond has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Black Diamond has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.52) | (0.55) | |
| Return On Capital Employed | (0.62) | (0.65) | |
| Return On Assets | (0.52) | (0.55) | |
| Return On Equity | (0.71) | (0.67) |
Things to note about Black Diamond Therap performance evaluation
Checking the ongoing alerts about Black Diamond for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Black Diamond Therap help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Black Diamond Therap generated a negative expected return over the last 90 days | |
| Black Diamond Therap has high historical volatility and very poor performance | |
| Black Diamond Therap has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (82.44 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Black Diamond Therapeutics currently holds about 160.89 M in cash with (66.72 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.43, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Black Diamond Therap has a frail financial position based on the latest SEC disclosures | |
| Over 99.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from gurufocus.com: T. Rowe Price Investment Management, Inc. Expands Stake in Black Diamond Therapeutics Inc |
- Analyzing Black Diamond's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Black Diamond's stock is overvalued or undervalued compared to its peers.
- Examining Black Diamond's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Black Diamond's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Black Diamond's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Black Diamond's stock. These opinions can provide insight into Black Diamond's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Black Stock Analysis
When running Black Diamond's price analysis, check to measure Black Diamond's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Black Diamond is operating at the current time. Most of Black Diamond's value examination focuses on studying past and present price action to predict the probability of Black Diamond's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Black Diamond's price. Additionally, you may evaluate how the addition of Black Diamond to your portfolios can decrease your overall portfolio volatility.